See also: Generic Detrol
Detrol LA is a brand name of tolterodine, approved by the FDA in the following formulation(s):
DETROL LA (tolterodine tartrate - capsule, extended release; oral)
Manufacturer: PHARMACIA AND UPJOHN
Approval date: December 22, 2000
Strength(s): 2MG, 4MG [RLD]
Has a generic version of Detrol LA been approved?
No. There is currently no therapeutically equivalent version of Detrol LA available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Detrol LA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
3,3-diphenylpropylamines and pharmaceutical compositions thereof
Patent 5,382,600
Issued: January 17, 1995
Inventor(s): Jonsson; Nils A. & Sparf; Bengt A. & Mikiver; Lembit & Moses; Pinchas & Nilvebrant; Lisbet & Glas; Gunilla
Assignee(s): Pharmacia Aktiebolag
##STR1## Novel 3,3-diphenylpropylamines of formula (I) wherein R.sup.1 signifies hydrogen or methyl, R.sup.2, R.sup.3 and R.sup.4 independently signify hydrogen, methyl, methoxy, hydroxy, carbamoyl, sulphanoyl or halogen, and X represents a tertiary amino group -NR.sup.5, R.sup.6, wherein R.sup.5 and R.sup.6 signify non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and which may form a ring together with the amine nitrogen, their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers, their use as drugs, especially as anticholinergic agents, their use for preparing an anticholinergic drug, pharmaceutical compositions containing the novel amines, and methods for preparing the same.Patent expiration dates:
- March 25, 2012
- September 25, 2012✓
- March 25, 2012
Pharmaceutical formulation and its use
Patent 6,630,162
Issued: October 7, 2003
Inventor(s): Lisbeth; Nilvebrant & Bengt; Hallen & Birgitta; Olsson & Jan; Strombom & Torkek; Gren & Anders; Ringberg & Martin; Wikberg
Assignee(s): Pharmacia AB
The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.Patent expiration dates:
- November 11, 2019✓✓
- May 11, 2020✓
- November 11, 2019
Therapeutic formulation for administering tolterodine with controlled release
Patent 6,770,295
Issued: August 3, 2004
Inventor(s): Bo; Kreilgård & Lene; Orup Jacobsen & Ulla; Hoeck & Helle; Kristensen & Torkel; Gren & Lisbeth; Nilvebrant & Anders; Ringberg & Martin; Wikberg & Bengt; Hallén & Birgitta; Olsson & Jan; Strömbom
Assignee(s): Pharmacia AB
The present invention is drawn to a method of treating an unstable or overactive urinary bladder by treating the patient with tolterodine or a tolterodine-related compound, or pharmaceutically acceptable salt thereof, with a controlled release formulation that maintains a substantially constant serum level of the active moiety or moieties for at least 24 hours. The present invention is further drawn to a formulation for the method.Patent expiration dates:
- August 26, 2019✓✓
- February 26, 2020✓
- August 26, 2019
Controlled release bead, a method of producing the same and multiple unit formulation comprising it
Patent 6,911,217
Issued: June 28, 2005
Inventor(s): Gren; Torkel & Ringberg; Anders & Wikberg; Martin & Wald; Randy J.
Assignee(s): Pharmacia AB
A controlled release bead comprises: (i) a core unit of a substantially water-soluble or water-swellable inert material; (ii) a first layer on the core unit of a substantially water-insoluble polymer; (iii) a second layer covering the first layer and containing an active ingredient; and (iv) a third layer of polymer on the second layer effective for controlled release of the active ingredient, wherein the first layer is adapted to control water penetration into the core. A method of producing the controlled release bead is also disclosed.Patent expiration dates:
- August 26, 2019✓✓
- February 26, 2020✓✓✓
- August 26, 2019
See also...
- Detrol LA Extended-Release Capsules Consumer Information (Wolters Kluwer)
- Detrol LA Consumer Information (Cerner Multum)
- Detrol LA Advanced Consumer Information (Micromedex)
- Tolterodine Consumer Information (Wolters Kluwer)
- Tolterodine Extended-Release Capsules Consumer Information (Wolters Kluwer)
- Tolterodine Consumer Information (Cerner Multum)
- Tolterodine Advanced Consumer Information (Micromedex)
- Tolterodine Tartrate AHFS DI Monographs (ASHP)
No comments:
Post a Comment